Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Condition(s):Colorectal Cancer Stage IVLast Updated:March 13, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Colorectal Cancer Stage IVLast Updated:March 13, 2023Recruiting
Condition(s):Hepatocellular CarcinomaLast Updated:March 19, 2019Unknown status
Condition(s):Advanced Gastric/Gastroesophageal Junction AdenocarcinomaLast Updated:March 20, 2024Not yet recruiting
Condition(s):Adenocarcinoma of Small Intestine; Appendix Carcinoma; MetastaticLast Updated:February 28, 2023Recruiting
Condition(s):Lung NeoplasmsLast Updated:August 14, 2020Unknown status
Condition(s):NsclcLast Updated:February 5, 2020Unknown status
Condition(s):Advanced Renal Cell CarcinomaLast Updated:March 28, 2024Recruiting
Condition(s):Advanced Solid TumorsLast Updated:December 28, 2023Recruiting
Condition(s):Hepatocellular Carcinoma; Portal Vein Tumor ThrombosisLast Updated:July 7, 2020Unknown status
Condition(s):Hepatocellular CarcinomaLast Updated:January 19, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.